These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31085108)

  • 1. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
    Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
    Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial.
    Mazard T; Mollevi C; Loyer EM; Léger J; Chautard R; Bouché O; Borg C; Armand-Dujardin P; Bleuzen A; Assenat E; Lecomte T
    Cancer Imaging; 2024 Jun; 24(1):77. PubMed ID: 38886836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
    Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
    Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
    Mazard T; Boonsirikamchai P; Overman MJ; Asran MA; Choi H; Herron D; Eng C; Maru DM; Ychou M; Vauthey JN; Loyer EM; Kopetz S
    Gut; 2018 Jun; 67(6):1095-1102. PubMed ID: 29084828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
    Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
    Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Rim on MDCT of Colorectal Liver Metastases: Assessment of Ability to Predict Progression-Free Survival and Response to Bevacizumab-Based Chemotherapy.
    Cheng J; Qiu M; Zhang Y; Hong N; Shen D; Zhou J; Wang Y
    AJR Am J Roentgenol; 2020 Dec; 215(6):1377-1383. PubMed ID: 32991216
    [No Abstract]   [Full Text] [Related]  

  • 7. Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
    Berardi G; De Man M; Laurent S; Smeets P; Tomassini F; Ariotti R; Hoorens A; van Dorpe J; Varin O; Geboes K; Troisi RI
    Eur J Surg Oncol; 2018 Jul; 44(7):1069-1077. PubMed ID: 29615295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
    Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab.
    Li S; Yuan L; Yue M; Xu Y; Liu S; Wang F; Liu X; Wang F; Deng J; Sun Q; Liu X; Xue C; Lu T; Zhang W; Zhou J
    Cancer Imaging; 2023 Mar; 23(1):30. PubMed ID: 36964617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
    J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
    Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
    AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.
    Chun YS; Vauthey JN; Boonsirikamchai P; Maru DM; Kopetz S; Palavecino M; Curley SA; Abdalla EK; Kaur H; Charnsangavej C; Loyer EM
    JAMA; 2009 Dec; 302(21):2338-44. PubMed ID: 19952320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Attenuation Distribution Across the Long Axis of Breast Cancer Liver Metastases at CT: A Quantitative Biomarker for Predicting Overall Survival.
    Abramson RG; Lakomkin N; Hainline A; Kang H; Hutson MS; Arteaga CL
    AJR Am J Roentgenol; 2018 Jan; 210(1):W1-W7. PubMed ID: 29064750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
    Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI.
    Liu LH; Zhou GF; Lv H; Wang ZC; Rao SX; Zeng MS
    Eur Radiol; 2021 Aug; 31(8):5640-5649. PubMed ID: 33449175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
    Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular volume fraction can predict the treatment response and survival outcome of colorectal cancer liver metastases.
    Li S; Yang X; Lu T; Yuan L; Zhang Y; Zhao J; Deng J; Xue C; Sun Q; Liu X; Zhang W; Zhou J
    Eur J Radiol; 2024 Jun; 175():111444. PubMed ID: 38531223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrast-Enhanced Computed Tomography Evaluation of Hepatic Metastases in Breast Cancer Patients Before and After Cytotoxic Chemotherapy or Targeted Therapy.
    He H; Cai C; Charnsangavej C; Theriault RL; Green M; Quraishi MA; Yang WT
    Can Assoc Radiol J; 2015 Nov; 66(4):356-62. PubMed ID: 26165625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.
    Amadori M; Barone D; Scarpi E; Oboldi D; Amadori E; Bandi G; Rossi A; Ferroni F; Ragazzini A; Casadei Gardini A; Frassineti GL; Gavelli G; Passardi A
    Eur Radiol; 2018 Jul; 28(7):2969-2978. PubMed ID: 29417252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
    Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
    Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.